Fundz Deep Dive
Everything you need to win Metabolon — in one platform.
Who to reach, what to say, and why now on Metabolon — plus every funding round, exec hire, and M&A move that follows, each with the verified contact and the outreach written for you.
Get the full Deep Dive on Metabolon — free.
One free Deep Dive, emailed to you. No spam; unsubscribe anytime.
Ready now? Choose your plan · Request a demo · Sign in
Metabolon and the Scottish Early Rheumatoid Arthritis (SERA) Study Announce Partnership to Identify Rheumatoid Arthritis Biomarkers
Contract Type
partnership
Description
Metabolon, Inc. and the Scottish Early Rheumatoid Arthritis (SERA) Study have announced a partnership to identify circulating small molecules as biomarkers of rheumatoid arthritis, aiming to improve the understanding of disease risk, progression, and treatment response. The partnership will combine metabolomic data with clinical and genomic information to reveal the molecular mechanisms of rheumatoid arthritis development and progression.